CymaBay Therapeutics (CBAY) Appoints Eric Lefebvre to its Board

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors.

“We are excited to be welcoming Éric to the Board. Éric’s extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us through our next phase of development and commercialization,” said Dr. Robert Wills, CymaBay’s Chairman of the Board.

“We are incredibly fortunate to be able to add such extensive experience and critical skill sets to our Board as we advance seladelpar through late-stage clinical development towards regulatory approval and commercialization,” concluded President and Chief Executive Officer, Sujal Shah. “Éric’s expertise in liver disease and strategic leadership in the industry will compliment the talents and contributions of our existing Board members to help us achieve our goal to bring new treatments to patients in need.”

“I’m looking forward to supporting CymaBay’s mission of improving the lives of patients with rare liver disease as a member of the Board,” said Dr. Lefebvre. “Having followed the seladelpar development program over the past few years at multiple medical meetings, I believe data to date have been encouraging and am excited about the potential for seladelpar to address unmet needs for patients with primary biliary cholangitis.”

You May Also Be Interested In

• Phoenix Education Partners names Robert Brackenbury to its board
• Astrana Health names two executives to expand leadership team
• Paulo Fontoura resigns from Lakefront Biotherapeutics board